Giulia Balconi has a background in finance and public health, and is currently at Adjuvant Capital, a life sciences investment firm focused on global health. At Adjuvant, she is engaged in the entire investment process, while also driving impact measurement and reporting. She has supported Adjuvant’s efforts on a number of portfolio companies including as Board observer for LimmaTech Biologics and InDevR, and Board member for VitriVax. Prior to Adjuvant Capital, she was an investment banker at J.P. Morgan, and she worked as Commercial Strategy and Analytics Manager at Natera, a biotech company focused on cell-free DNA testing for women’s health, oncology, and organ health. She was also involved in projects in the digital health space, with the startup Cornerstone AI, and in health policy and management research, with UC Berkeley School of Public Health. Giulia has an MPH from UC Berkeley and graduated with honors from Bocconi University.